{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2"},{"groupId":"OG001","value":"46.2"},{"groupId":"OG002","value":"48.6"},{"groupId":"OG003","value":"49.9"},{"groupId":"OG004","value":"49.7"},{"groupId":"OG005","value":"49.1"}]}],"title":"SF-36 MCS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8"},{"groupId":"OG001","value":"69.1"},{"groupId":"OG002","value":"71.1"},{"groupId":"OG003","value":"71.3"},{"groupId":"OG004","value":"73.3"},{"groupId":"OG005","value":"71.3"}]}],"title":"SF-36 PCS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"423"},{"groupId":"OG001","value":"424"},{"groupId":"OG002","value":"395"},{"groupId":"OG003","value":"373"},{"groupId":"OG004","value":"344"},{"groupId":"OG005","value":"334"}],"units":"Participants"}],"description":"The SF-36 Health Survey is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL. The percentage of participants with at least a 5-point improvement from baseline is presented for each subscale.","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Using the 36-Item Short-Form Health Survey (SF-36) Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}